Transferable plasmid mediating resistance to multiple antimicrobial agents in Klebsiella pneumoniae isolates in Greece

Clinical Microbiology and Infection

Volumn 8, Issue 9, 2002, Pages 579-588

  Galani, I ^a   Xirouchaki, E ^a   Kanellakopoulou, K ^a   Petrikkos, G ^a   Giamarellou, H ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

Author keywords

Klebsiella pneumoniae; Resistance mechanisms; Transferable plasmid

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL ENZYME; BACTERIOCIN; BETA LACTAMASE; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DNA; GENTAMICIN; IMIPENEM; KANAMYCIN; MEROPENEM; NEOMYCIN; NETILMICIN; SISOMICIN; TETRACYCLINE; TOBRAMYCIN;

ACETYLATION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CONJUGATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME SYNTHESIS; ESCHERICHIA COLI; GREECE; ISOELECTRIC FOCUSING; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE;

EID: 0036751668     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00391.x     Document Type: Article

References (43)

1. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24(suppl 1): S19-45.
2. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991; 35: 1697-704.
3. Podbielski A, Schonling J, Melzer B, Warnatz K, Leusch H-G. Molecular characterization of a new plasmid-encoded SHV-type β-lactamase (SHV-2 variant) conferring high level cefotaxime resistance upon Klebsiella pneumoniae. J Gen Microbiol 1991; 137: 569-78.
4. Prinarakis EE, Tzelepi E, Gazouli M, Mentis AF, Tzouvelekis LS. Characterization of a novel SHV beta-lactamase variant that resembles the SHV-5 enzyme. FEMS Microbiol Lett 1996; 139: 229-34.
5. Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouvelekis LS. Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from SHV-5 variant. Antimicrob Agents Chemother 1997; 41: 838-40.
6. Giamarellou H. Surveillance of gram-negative resistance in Greece in 1994: The third Amphiaraion Study [abstract 0609]. In: Program and Abstracts of the 19th International Congress of Chemotherapy. Montreal: Pulses Group Inc., 1995: 282C.
7. Vatopoulos AC, Philippon A, Tzouvelekis LS, Komninou Z, Legakis NJ. Prevalence of a transferable SHV-5 type β-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. J Antimicrob Chemother 1990; 26: 635-48.
8. Gutmann L, Ferre B, Goldstein FW et al. SHV-5, a novel SHV-type β-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams. Antimicrob Agents Chemother 1989; 33: 951-6.
9. Van Gijsegem F, Toussaint A. Chromosome transfer and R-prime formation by an RP4::mini-Mu derivative in Escherichia coli Salmonella typhimurium, Klebsiella pneumoniae and Proteus mirabilis. Plasmid 1982; 7: 30-44.
10. Bauernfeind A, Petermuller C, Schneider R. Bacteriocins as tools in analysis of nosocomial Klebsiella pneumoniae infections. J Clin Microbiol 1981; 33: 15-19.
11. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacteria genomes. Nucleic Acids Res 1991; 19: 6823-31.
12. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotics susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45: 493-6.
13. Jarlier V, Nicolas M-H, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 4: 867-78.
14. Legrand P, Fournier G, Bure A et al. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals. Eur J Clin Microbiol Infect Dis 1989; 8: 527-9.
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, ninth informational supplement. M100-S9 (M2-A6). Villanova, PA: NCCLS, 1999.
16. Miller GH, Sabatelli FJ, Hare RS, Waitz JA. Survey of aminoglycoside resistance patterns. Dev Industrial Microbiol 1980; 21: 91-104.
17. Miller GH, Hare RS, Shaw KJ, Sabatelli FJ. Aminoglycoside resistance mechanisms booklet. Manati: Schering-Plough Research, 1989.
18. Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 1990; 18(5): 294-8.
19. Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol 1981; 145: 1365-73.
20. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Plainview: Cold Spring Harbor Laboratory Press, 1989.
21. Billot-Klein D, Gutmann L, Collatz E. Nucleotide sequence of the SHV-5 β-lactamase gene of the Klebsiella pneumoniae plasmid. Antimicrob Agents Chemother 1990; 34: 2439-41.
22. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-17.
23. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; ii: 302-6.
24. Sirot D, Sirot J, Labia R et al. Transferable resistance to third generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 1987; 20: 323-34.
25. Spencer RC, Wheat PF, Winstanley TG, Cox DM, Plested SJ. Novel β-lactamase in a clinical isolate of Klebsiella pneumoniae conferring unusual resistance to β-lactam antibiotics. J Antimicrob Chemother 1987; 20: 919-27.
26. Vuye A, Verschraegen G, Claeys G. Plasmid mediated β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli resistant to ceftazidime. Antimicrob Agents Chemother 1989; 33: 757-61.
27. Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 1131-6.
28. Jacoby GA, Sutton L. Properties of plasmids responsible for extended-spectrum β-lactamase production. Antimicrob Agents Chemother 1991; 35: 164-9.
29. Philippon A, Ben Redjeb S, Fournier G, Ben Hassen A. Epidemiology of extended-spectrum β-lactamases. Infection 1989; 17: 347-54.
30. Smith CE, Tillman BS, Howell AW, Longfield RN, Jorgensen JH. Failure of ceftazidime-amikacin therapy for bacteremia. and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamase. Antimicrob Agents Chemother 1990; 34: 1290-3.
31. Saunders JR. Genetics and evolution of antibiotic resistance. Br Med Bull 1984; 40: 54-60.
32. Petit A, Gerbaund G, Sirot D, Courvalin P, Sirot J. Molecular epidemiology of TEM-3 (CTX-1) β-lactamase. Antimicrob Agents Chemother 1990; 34: 219-24.
33. Chanal CM, Sirot DL, Petit A et al. Multiplicity of TEM-derived β-lactamases from Klebsiella, pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids. Antimicrob Agents Chemother 1989; 33: 1915-20.
34. Rice LB, Willey SH, Papanicolaou GA et al. Out-break of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990; 34: 2193-9.
35. Nuesch-Inderbinen MT, Kayser FH, Hachler H. Survey and molecular genetics of SHV β-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob Agents Chemother 1997; 41: 943-9.
36. Sirot D, Chanal C, Labia R, Meyran M, Sirot J, Cluzel R. Comparative study of five plasmid-mediated ceftazidimases isolated in Klebsiella pneumoniae. J Antimicrob Chemother 1989; 24: 509-21.
37. Shannon KP, King A, Phillips I, Nicolas MH, Philippon A. Importation of organisms producing broad-spectrum SHV-group β-lactamases into the United Kingdom. J Antimicrob Chemother 1990; 25: 343-51.
38. The Aminoglycoside Resistance Study Groups. The most frequently occurring aminoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. J Chemother 1995; 7(suppl 2): 17-30.
39. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ, the Aminoglycoside Resistance Study Groups. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin-a new broad-spectrum aminoglycoside. J Chemother 1995; 7(suppl 2): 31-44.
40. Petrikkos G, Stamos G, Grammatikou M, Xirouchaki E, Miller G, Giamarellou H. Survey of the aminoglycoside resistance mechanisms in gram-negative bacteria [abstract 190]. In: 18th International Congress of Chemotherapy, Stockholm: 1993: 190.
41. Miller GH, Sabatelli FJ, Hare RS et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin Infect Dis 1997; 24(suppl 1): S46-62.
42. Pena C, Pujol M, Ardanuy C et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42(1): 53-8.
43. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 28(14): 1233-7.